Contact: Cindy Starr
(513) 558-3505
[email protected]
CINCINNATI – A multi-site study of a new deep brain stimulation device for people with Parkinson’s disease has found the device to provide benefits to patients, potentially paving the way for unprecedented competition in the area of neurostimulation technology.
The study, whose co-authors included George Mandybur, MD, above left, a Mayfield Clinic neurosurgeon and Associate Professor of Neurosurgery, and Fredy J. Revilla, MD, above right, a UC Health neurologist and Associate Professor of Neurology, was published January 11, 2023 in the online edition of Lancet Neurology. Drs. Mandybur and Revilla are members of the James J. and Joan A. Gardner Center for Parkinson’s Disease at the University of Cincinnati (UC) Neuroscience Institute, a specialty center within UC Health.
Principal investigator of the study was Michael Okun, MD, a neurologist and Co-director of the Center for Movement Disorders and Neurorestoration at the University of Florida College of Medicine.
Deep brain stimulation (DBS) devices stimulate the subthalamic nucleus deep within the brain. Deep brain stimulation surgery has been shown to reduce symptoms of Parkinson’s and to improve quality of life.
The Lancet Neurology study examined the new Libra and LibraXP devices, which are manufactured by St. Jude Medical and which provide a constant, fixed-dose current. Medtronic, Inc., the only manufacturer with a DBS device currently approved by the U.S. Food and Drug Administration (FDA), recently added a controlled-current option to its longstanding voltage-controlled stimulator.
Participants in the randomized, controlled trial whose stimulators were turned on shortly after surgery experienced an increase of four hours of “on time” (with minimal symptoms), 3 months into the study. These benefits were significantly greater – 2.5 more hours of “on time” — than those experienced by participants in the control group, whose stimulators were not turned on until the three-month mark.
Dr. Mandybur, who implanted the devices in 12 study participants at UC Health / University Hospital, said the constant-current device compares favorably with the voltage-controlled device currently in widespread use. “This is the first study to look at constant-current effectiveness in Parkinson’s disease,” Dr. Mandybur says. “The new device appeared to be every bit as effective as the voltage-controlled device, but we won’t know for sure until there is a head-to-head comparison in future clinical trials. The devices are not identical.”
“With further study,” Dr. Revilla says, “we may be able to establish clearly the differences and similarities of these two technologies.”
The St. Jude Neuromodulation Division, which funded the study, has applied for and is awaiting approval from the FDA for the Libra and LibraXP neurostimulators, which are currently available Europe, Latin America and Australia.
The study results likely signal the imminent arrival of a competitor into a market that Medtronic alone has occupied. “It will stir competition and it will light fires under people to develop new technology,” Dr. Mandybur says. “The same thing happened in the area of spinal cord stimulators.”
Researchers theorize that constant-current stimulation might provide more accurate control of the spread of the electrical field than voltage-controlled stimulation. “But fundamental differences are unlikely,” writes Jens Volkmann, MD, of University Hospital of Würzburg, Germany, in an accompanying editorial in Lancet Neurology.
Parkinson’s disease, which afflicts more than 1million Americans, is a degenerative neurological disorder involving the death of dopamine-producing nerve cells deep within the brain. There is no cure for Parkinson’s at this time, and scientists do not yet know how to halt its progression. Recent studies have shown that neurostimulation may slow the progression of the disease.
Candidates for deep brain stimulation are those who respond well to dopamine but over time have developed intolerable side-effects (mainly dyskinesias) and short duration of benefit. “When a person with Parkinson’s develops wide motor fluctuations, requiring frequent doses of medications, along with intolerable side effects, it is time for DBS surgery,” Dr. Revilla says. “But it is still a requirement that the patient experience some benefit from the medications, even if it is short-lived.”
Dr. Revilla praised the 15 institutions whose close collaboration resulted in a study “that we expect will allow us to have alternative options for programming deep brain stimulation in patients who don’t respond well to conventional medical treatments.”
The Gardner Center team proved its mettle as a bustling movement disorders center by enrolling 12 patients, the second highest number of any of the participating centers. (The highest enrollment was 13.)
* * *
Disclosures: George Mandybur, MD, has received honoraria from Medtronic, Inc. Fredy J. Revilla, MD, is a consultant for Lundbeck, Inc.
* * *
The UC Neuroscience Institute, a regional center of excellence, is dedicated to patient care, research, education, and the development of new treatments for stroke, brain and spinal tumors, epilepsy, traumatic brain and spinal injury, Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, disorders of the senses (swallowing, voice, hearing, pain, taste and smell), and psychiatric conditions (bipolar disorder, schizophrenia, and depression).
